Anzeige
Mehr »
Login
Donnerstag, 01.05.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Renaissance der Kernkraft: Mit dieser Aktie können Sie jetzt vom neuen Uran-Boom profitieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
469 Leser
Artikel bewerten:
(2)

Pulsenmore Ltd.: Pulsenmore Expands Partnership with Clalit Health Services to Deliver 25,000 Home Ultrasound Devices for Remote Prenatal Care

Finanznachrichten News

RAMAT GAN, Israel, Oct. 30, 2024 /PRNewswire/ -- Pulsenmore (TASE: PULS), a pioneering provider of home-based ultrasound technology, has announced the renewal and expansion of its strategic partnership with Clalit Health Services, Israel's largest HMO. Over the next five years, Pulsenmore will supply 25,000 units of its advanced home ultrasound devices to support Clalit's commitment to accessible, high-quality prenatal care.

Pulsenmore is a digital prenatal care platform that enables ultrasound imaging and care from home. Prescribed by a physician, the solution enhances access to care and resource management

Under the new agreement, Pulsenmore's devices will enable pregnant women to conduct ultrasound scans at home, both asynchronously (App Guided) and, for the first time, synchronously (Clinician Guided) with real-time video consultations. This feature will allow real-time monitoring and guidance, empowering expectant mothers with accessible, quality prenatal care directly from their homes.

Additionally, Clalit will evaluate the incorporation of Pulsenmore's latest home-based Biophysical Profile (BPP) feature, into its services. The BPP enables medical teams to assess fetal well-being and make timely clinical decisions for high-risk pregnancies.

Pulsenmore's home ultrasound device, connected via smartphone, allows pregnant women to perform self-guided scans, which are securely sent to medical teams for remote review. This intuitive device captures essential fetal health metrics-such as heartbeat, movement, and amniotic fluid levels-providing comprehensive insights into fetal well-being.

Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore, commented, "Our new agreement with Clalit reinforces their trust in Pulsenmore's solutions as a transformative approach in remote healthcare. This partnership not only strengthens our commitment to providing more flexible, supportive care to Clalit's members, but it also shapes the way for advancing the future of prenatal care."

Founded in 2014, Pulsenmore has rapidly expanded its global footprint. The company has regulatory approvals in Israel and Europe (CE) and recently secured clearance for distribution in Australia and Brazil. In the fusion of telehealth and femtech, Pulsenmore has marked a year of significant milestones, as the company reported a robust 79% revenue growth in the first half and committed contractual revenue extending into 2025. With new distribution agreements in key markets and a strengthened pipeline, Pulsenmore is dedicated to transforming prenatal care by offering accessible healthcare solutions that empower families everywhere.

For more information, please visit www.pulsenmore.com

Press Contact:
Mira Altmark Sofer
Vice President Global Marketing, Pulsenmore
mira@pulsenmore.com
+972-50-5911212

Photo: https://mma.prnewswire.com/media/2543344/Pulsenmore.jpg

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/pulsenmore-expands-partnership-with-clalit-health-services-to-deliver-25-000-home-ultrasound-devices-for-remote-prenatal-care-302290398.html

© 2024 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.